# Non-Viral TCR Gene Therapy

> **NCT04102436** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Endocrine/Neuroendocrine
- Non-Small Cell Lung Cancer
- Breast Cancer
- Gastrointestinal/Genitourinary Cancers
- Ovarian Cancer

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Aldesleukin
- **BIOLOGICAL:** Sleeping Beauty Transposed PBL

## Key facts

- **NCT ID:** NCT04102436
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-03-08
- **Primary completion:** 2024-03-08
- **Final completion:** 2024-03-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulty with availability of GLP-grade reagents for manufacturing.
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102436, "Non-Viral TCR Gene Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04102436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*